Analyst Yun Zhong of Wedbush maintained a Buy rating on Ascendis Pharma (ASND – Research Report), retaining the price target of $181.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Yun Zhong’s rating is based on several factors surrounding Ascendis Pharma’s recent developments and market positioning. The company recently launched Yorvipath in the U.S., a treatment for hypoparathyroidism, which is expected to gain traction among clinicians and patients due to its promising clinical profile. This treatment addresses a significant unmet need in the market, providing a novel hormone replacement therapy for a condition that previously lacked effective options.
Moreover, Ascendis Pharma’s strong research foundation, particularly in metabolic bone diseases, further supports the optimistic outlook for Yorvipath’s adoption. The competitive landscape in hypoparathyroidism shows limited alternatives, positioning Ascendis Pharma favorably. These elements combined suggest potential for increased market share and revenue growth, underpinning Yun Zhong’s Buy rating for the company’s stock.
In another report released on January 29, J.P. Morgan also maintained a Buy rating on the stock with a $167.00 price target.